GSK - GSK's Experimental Asthma Drug Reduces Severe Attacks Phase 3 Trial Data Shows | Benzinga
Tuesday, GSK plc (NYSE:GSK) released headline results from the phase III clinical trials SWIFT-1 and SWIFT-2, which assessed the efficacy and safety of depemokimab versus placebo in adults and adolescents with severe asthma with type 2 inflammation characterized by blood eosinophil count.
Earlier this year, GSK acquired Aiolos Bio Inc., a privately held asthma drug maker, for $1 billion.
Both SWIFT-1 and SWIFT-2 met their primary endpoints of a reduction in the annualized rate of clinically significant exacerbations (asthma attacks) over 52 weeks.
Across ...